CY1107542T1 - Μiα ουσιαστικa κρυσταλλικh μορφh μελαγατρaνης - Google Patents

Μiα ουσιαστικa κρυσταλλικh μορφh μελαγατρaνης

Info

Publication number
CY1107542T1
CY1107542T1 CY20061101785T CY061101785T CY1107542T1 CY 1107542 T1 CY1107542 T1 CY 1107542T1 CY 20061101785 T CY20061101785 T CY 20061101785T CY 061101785 T CY061101785 T CY 061101785T CY 1107542 T1 CY1107542 T1 CY 1107542T1
Authority
CY
Cyprus
Prior art keywords
melagatran
substantive
crystal form
crystalline
forms
Prior art date
Application number
CY20061101785T
Other languages
English (en)
Inventor
Lena HEDSTRÖM
Anita Lundblad
Sofia NÅGÅRD
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of CY1107542T1 publication Critical patent/CY1107542T1/el

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06008—Dipeptides with the first amino acid being neutral
    • C07K5/06078—Dipeptides with the first amino acid being neutral and aromatic or cycloaliphatic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Liquid Crystal Substances (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Enzymes And Modification Thereof (AREA)

Abstract

Δίδεται μελαγατράνη με μία μορφή που είναι ουσιαστικά κρυσταλλική. Βρέθηκε ότι οι κρυσταλλικές μορφές μελαγατράνης έχουν μία υψηλή και στερεής κατάστασης σταθερότητα, όταν συγκρίνονται με τις άμορφες μορφές της ένωσης.
CY20061101785T 1999-07-02 2006-12-12 Μiα ουσιαστικa κρυσταλλικh μορφh μελαγατρaνης CY1107542T1 (el)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
SE9902550A SE9902550D0 (sv) 1999-07-02 1999-07-02 New crystalline forms
EP00946687A EP1196431B1 (en) 1999-07-02 2000-06-30 A substantially crystalline form of melagatran

Publications (1)

Publication Number Publication Date
CY1107542T1 true CY1107542T1 (el) 2013-03-13

Family

ID=20416364

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20061101785T CY1107542T1 (el) 1999-07-02 2006-12-12 Μiα ουσιαστικa κρυσταλλικh μορφh μελαγατρaνης

Country Status (33)

Country Link
US (1) US6479078B1 (el)
EP (1) EP1196431B1 (el)
JP (1) JP2003503508A (el)
KR (1) KR20020020765A (el)
CN (1) CN100537598C (el)
AR (1) AR035553A1 (el)
AT (1) ATE339438T1 (el)
AU (1) AU765614B2 (el)
BR (1) BR0012035A (el)
CA (1) CA2376944A1 (el)
CY (1) CY1107542T1 (el)
CZ (1) CZ20014722A3 (el)
DE (1) DE60030723T2 (el)
DK (1) DK1196431T3 (el)
EE (1) EE200100646A (el)
ES (1) ES2270849T3 (el)
HK (1) HK1045529B (el)
HU (1) HUP0202322A3 (el)
IL (1) IL146972A0 (el)
IS (1) IS6215A (el)
MX (1) MXPA01013441A (el)
MY (1) MY122760A (el)
NO (1) NO20016419L (el)
NZ (1) NZ516187A (el)
PL (1) PL352872A1 (el)
PT (1) PT1196431E (el)
RU (1) RU2243973C2 (el)
SE (1) SE9902550D0 (el)
SK (1) SK18832001A3 (el)
TR (1) TR200103855T2 (el)
TW (1) TWI250991B (el)
WO (1) WO2001002426A1 (el)
ZA (1) ZA200109944B (el)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6976012B1 (en) 2000-01-24 2005-12-13 Sony Corporation Method and apparatus of using a neural network to train a neural network
AR035216A1 (es) * 2000-12-01 2004-05-05 Astrazeneca Ab Derivados de acido mandelico ,derivados farmaceuticamente aceptables, uso de estos derivados para la fabricacion de medicamentos, metodos de tratamiento ,procesos para la preparacion de estos derivados, y compuestos intermediarios
US7129233B2 (en) * 2000-12-01 2006-10-31 Astrazeneca Ab Mandelic acid derivatives and their use as thrombin inhibitors
AR034517A1 (es) * 2001-06-21 2004-02-25 Astrazeneca Ab Formulacion farmaceutica
SE0201659D0 (sv) * 2002-05-31 2002-05-31 Astrazeneca Ab Modified release pharmaceutical formulation
SE0201661D0 (sv) 2002-05-31 2002-05-31 Astrazeneca Ab New salts
US7781424B2 (en) * 2003-05-27 2010-08-24 Astrazeneca Ab Modified release pharmaceutical formulation
JP4748449B2 (ja) * 2003-11-27 2011-08-17 味の素株式会社 フェニルアラニン誘導体の結晶及びその製造方法
US20050209211A1 (en) * 2004-03-16 2005-09-22 Devalina Law Trihemihydrate, anhydrate and novel hydrate forms of Cefdinir
US7524354B2 (en) * 2005-07-07 2009-04-28 Research Foundation Of State University Of New York Controlled synthesis of highly monodispersed gold nanoparticles
TW200827336A (en) * 2006-12-06 2008-07-01 Astrazeneca Ab New crystalline forms
US20090061000A1 (en) * 2007-08-31 2009-03-05 Astrazeneca Ab Pharmaceutical formulation use 030

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH0687881A (ja) * 1992-09-07 1994-03-29 Asahi Chem Ind Co Ltd ロキタマイシン・一水和物結晶、及びその製造法
JP3077925B2 (ja) * 1992-12-15 2000-08-21 ヤマサ醤油株式会社 ２’−デオキシ−２’−メチリデンシチジン無水物結晶およびその製造法
SE9301916D0 (sv) 1993-06-03 1993-06-03 Ab Astra New peptides derivatives
SE9404196D0 (sv) * 1994-12-02 1994-12-02 Astra Ab New antithrombotic formulation
JP3182685B2 (ja) * 1995-09-01 2001-07-03 北陸製薬株式会社 水和物結晶及びその製造方法
JP2914324B2 (ja) * 1995-10-23 1999-06-28 味の素株式会社 ピペリジン誘導体の結晶並びにその製造中間体及び製造方法
TWI238827B (en) * 1995-12-21 2005-09-01 Astrazeneca Ab Prodrugs of thrombin inhibitors
SE9603724D0 (sv) * 1996-10-11 1996-10-11 Astra Ab New pharmaceutical parenteral formulation of a thrombin inhibitor
SE9802974D0 (sv) 1998-09-03 1998-09-03 Astra Ab New crystalline forms
FR2793418B1 (fr) * 1999-05-11 2001-07-27 Synthelabo Formulations galeniques d'agents antithrombotiques pour administration sous-cutanee

Also Published As

Publication number Publication date
KR20020020765A (ko) 2002-03-15
EP1196431B1 (en) 2006-09-13
CN100537598C (zh) 2009-09-09
HK1045529B (zh) 2007-02-23
US6479078B1 (en) 2002-11-12
HUP0202322A2 (en) 2002-10-28
SE9902550D0 (sv) 1999-07-02
BR0012035A (pt) 2002-03-19
WO2001002426A1 (en) 2001-01-11
EP1196431A1 (en) 2002-04-17
JP2003503508A (ja) 2003-01-28
CZ20014722A3 (cs) 2002-05-15
CN1359389A (zh) 2002-07-17
AU6040800A (en) 2001-01-22
ZA200109944B (en) 2003-03-03
DE60030723T2 (de) 2007-11-08
TR200103855T2 (tr) 2002-04-22
IL146972A0 (en) 2002-08-14
PT1196431E (pt) 2007-01-31
MY122760A (en) 2006-05-31
TWI250991B (en) 2006-03-11
MXPA01013441A (es) 2002-07-02
DE60030723D1 (de) 2006-10-26
IS6215A (is) 2001-12-27
NO20016419L (no) 2002-03-01
CA2376944A1 (en) 2001-01-11
AR035553A1 (es) 2004-06-16
ES2270849T3 (es) 2007-04-16
PL352872A1 (en) 2003-09-08
HK1045529A1 (en) 2002-11-29
AU765614B2 (en) 2003-09-25
ATE339438T1 (de) 2006-10-15
NO20016419D0 (no) 2001-12-28
SK18832001A3 (sk) 2002-10-08
RU2243973C2 (ru) 2005-01-10
EE200100646A (et) 2003-02-17
HUP0202322A3 (en) 2003-04-28
DK1196431T3 (da) 2006-12-11
NZ516187A (en) 2004-09-24

Similar Documents

Publication Publication Date Title
CY1107542T1 (el) Μiα ουσιαστικa κρυσταλλικh μορφh μελαγατρaνης
PT1109812E (pt) Pirrolobenzodiazepinas
UY34152A (es) ?oxazolidinonas substituidas y su uso?.
DK0977741T3 (da) Substituerede phenylderivater, deres fremstilling og anvendelse
DE60022670D1 (de) Wiedreverschliessbare ausgabeverpackung
EE200200130A (et) Uued farmatseutiliste omadustega aminodikarboksüülhappe derivaadid
DK1165516T3 (da) Heterocyklisk urinstof og beslægtede forbindelser, der er nyttige som antiinflammatoriske midler
AR023777A1 (es) Nuevos compuestos
AU6989800A (en) Diamino-1,2,4-triazole-carboxylic and derivatives as gsk-3 inhibitors
TR200100700T2 (tr) EtO2C--CH2-(R)Cgl-Aze-Pab-OH'nin kristalin formları
EA200200510A1 (ru) 4-карбоксиамино-2-этил-1,2,3,4-тетрагидрохинолин в кристаллической форме как ингибитор сетр
DE60022768D1 (de) Polarisationsinterferometer mit verminderten Geistern
TR200002605T2 (tr) Nitrik oksit sentaz inhibitörleri olarak faydalı halojene amidino amino asit türevleri
AU3966600A (en) Haloalkoxy imidazonaphthyridines
PT956286E (pt) Sintese de terfenadina e derivados
CO4940463A1 (es) Macrolidas cristalinas
AR022321A1 (es) Derivados de anticonvulsivo utiles para el tratamiento de la migrana transformada
AU2002220722A1 (en) Use of propylene terpolymers for the production of films
DE69929201D1 (de) Verbesserte Verzögerungsregelschleife
DE60024760D1 (de) Einlagerungsverbindung
TR200001122T2 (tr) Farmasötikler olarak bifenil türevleri.
NO20000094D0 (no) 6-Azaurcilderivater som IL-5 inhibitorer
AU3836700A (en) Disubstituted benzene derivatives
ATE289302T1 (de) Heterozyklische verbindungen mit entzündungshemmender wirkung
ID27596A (id) Bentuk paroksetina kristal